Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Bruce Anthony Campbell CreeJeffrey L BennettHo Jin KimBrian G WeinshenkerSean J PittockDean WingerchukKazuo FujiharaFriedemann PaulGary R CutterRomain MarignierAri J GreenOrhan AktasHans-Peter HartungIan M WilliamsJorn DrappaDewei SheDaniel CimboraWilliam ReesJohn N RatchfordEliezer KatzPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
N-MOmentum demonstrated that inebilizumab provides a robust reduction in the risk of NMOSD attacks regardless of attack evaluation method, attack type, patient demographics, or previous therapy.The N-MOmentum study is registered at ClinicalTrials.gov: NCT2200770.